Tech Company Financing Transactions
Vivet Therapeutics Funding Round
Vivet Therapeutics, operating out of Paris, secured $5.3 million in investment from Bpifrance.
Transaction Overview
Company Name
Announced On
2/1/2024
Transaction Type
Venture Equity
Amount
$5,280,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to further develop its gene therapy product VTX-806 as an effective treatment option to stop or reverse disease progression over the long-term, or potentially cure CTX in patients.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
80 Boulevard Haussmann
Paris, 75008
France
Paris, 75008
France
Phone
Undisclosed
Website
Email Address
Overview
Vivet Therapeutics is a clinical-stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jean-Philippe Combal
Chief Financial Officer
Susan Coles
Chief Medical Officer
Bernard Bénichou
Chief Operating Officer
Anne Douar
Chief Scientific Officer
Gloria Gonzalez-Aseguinolaza
Browse more venture capital transactions:
Prev: 2/1/2024: DataSnipper venture capital transaction
Next: 2/1/2024: Greenerwave venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. All VC database entries on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs